Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 1;35(6):488–497. doi: 10.1089/jir.2014.0209

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2015, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 6. — Pretreatment with IFN-α±WY-14643 modulates IFN-α-induced AXL, SOCS1, and SOCS3 expression. IFN-α pretreatment upregulated the negative regulators of the IFN-α signaling pathway. When WY-14643 was added, AXL expression was reduced at baseline and 4 h post-IFN-α treatment. SOCS1 expression was reduced at 8 and 24 h post-IFN-α treatment, whereas SOCS3 expression was reduced at 4 and 8 h. *Significant difference between treatment and control, and significant difference between IFN and IFN plus WY-14643 treatment. Graphs demonstrate an average of 3 experimental replicates (P<0.05). SOCS, suppressor of cytokine signaling.

Inline graphic — Pretreatment with IFN-α±WY-14643 modulates IFN-α-induced AXL, SOCS1, and SOCS3 expression. IFN-α pretreatment upregulated the negative regulators of the IFN-α signaling pathway. When WY-14643 was added, AXL expression was reduced at baseline and 4 h post-IFN-α treatment. SOCS1 expression was reduced at 8 and 24 h post-IFN-α treatment, whereas SOCS3 expression was reduced at 4 and 8 h. *Significant difference between treatment and control, and significant difference between IFN and IFN plus WY-14643 treatment. Graphs demonstrate an average of 3 experimental replicates (P<0.05). SOCS, suppressor of cytokine signaling.